Exhaled nitric oxide test to detect asthmatic airway inflammation can help doctors determine whether or not steroids medications should be used as treatment. Breath tests can detect H. Pylori, associated with stomach ulcers and in some cases, stomach cancers. The measurement and analysis

of (volatile organic compounds) VOCs in exhaled breath in relations to many diseases and cancers have been widely studied with several highly effective clinical applications. Breathalyzer roadside test for alcohol, a 50-year old test, has resulted in dramatic fall in drink-driving related deaths.

Detect

Canary Health Technologies uses proven biomarkers and proprietary nanosensors in designing a handheld point of care mobile device to map the human breath and uncover hidden data for the improvement of human health. Combined with AI powered intelligence, Canary’s patent pending biomarker sensor technology can predict the risk of developing cancers, identifying presence of diseases, characterizing the nature and location of cancers, and predicting and monitoring responses to therapy.

Track

Ensuring patients take their medicines as prescribed is critical to positive health outcomes. Canary’s biosensors and dynamic database are also capable of monitoring and verify medication adherence and track disease outbreaks, all in real time. AI-powered technology can also accelerate drug development, helping novel treatments get to patients as quickly as possible.

Airostotlelc abx1 Sensor

Designed to overcome a variety of challenges that have confounded prior approaches to breath-based analysis and early-stage cancer and disease detection, AiroStotle™ can detect digital breath signatures’ biopatterns of diseases such as cancerous tumours with high clinical sensitivity and specificity. Digital biopatterns are based on proprietary sensor technology and VOC nanoparticle library.

• Non-invasive, requiring no blood draw or collection of body particulates other than breath

• Has potential to detect upwards of 90% of all cancers*

• Potential for high detection rate of early stage cancers*

• Cloud-processed breath data samples with results delivered to physicians, practitioners, and providers in near-real-time

• Detects other forms of diseases in addition to cancers*

*based on lab and/or bench testing

NanoSmart Technology

Patented NanoSmart™ technology coats any oral medication with a molecular layer that acts like a barcode. Combined with our proprietary nanoparticle biosensor, this enables real-time visibility to medication adherence and treatment compliance.

G2 BioSensor

The G2 BioSensor™ is a smart, handheld breath sensor technology that has the power to detect the medication you take in real-time using your breath. When combined with our NanoSmart technology, this enables detection of medication-specific compounds in your breath. Medication adherence verification occurs in real-time and verification is sent to the cloud and shared with your healthcare provider.

G2 BioSensor™ provides a next-generation solution to medication adherence tracking, enabling easier use and greater patient participation, and enabling greater insight into risk factors, treatment effectiveness, and patient health patterns, leading to more informed healthcare decisions for everyone involved.